Literature DB >> 23602340

Antipsychotics can modulate the cytokine profile in schizophrenia: attenuation of the type-2 inflammatory response.

Milica Borovcanin1, Ivan Jovanovic2, Gordana Radosavljevic2, Slavica Djukic Dejanovic3, Vesna Stefanovic4, Nebojsa Arsenijevic2, Miodrag L Lukic2.   

Abstract

OBJECTIVE: We recently reported that the type-2 cytokine response is increased in schizophrenia. The aim of this study was to analyse the effects of antipsychotic drugs on the serum levels of type-1 (TNF-α, IFN-γ), type-2 (IL-4, IL-10), type-17 (IL-17) and regulatory cytokines (TGF-β, IL-27 and IL-6).
METHODS: Cytokine measurements in the patients were performed on day 0 and day 30 of the treatment using standard ELISA assays. Three groups of subjects were studied: patients that were unmedicated with First Episode Psychosis (FEP; n=88), patients that were treated with antipsychotics with Schizophrenia in relapse (SC in relapse; n=45) and healthy controls (n=36).
RESULTS: TGF-β levels were increased in both patient groups and were further enhanced after treatment in the FEP group (p=0.014) but not in the SC relapse group. Antipsychotic treatment was correlated with lower levels of IL-4, IL-6 and IL-27 (p<0.005) in the FEP group. Finally, the serum levels of IL-17 were not significantly altered between the two measurements but were significantly lower in the FEP group (p<0.001) when compared with healthy controls. After therapy, patients with SC who were in relapse had decreased serum levels of IL-4 (p=0.006) and IL-6 (p=0.007). We also observed a weak negative correlation between the IFN-γ/TGF-β ratio and the total PANSS score and between the IL-17/TGF-β ratio and the negative and general psychopathology subscales.
CONCLUSION: The increased type-2 cytokine serum levels in schizophrenia appear to be downregulated by antipsychotic treatment.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23602340     DOI: 10.1016/j.schres.2013.03.027

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  26 in total

1.  Angiogenic and immune signatures in plasma of young relatives at familial high-risk for psychosis and first-episode patients: A preliminary study.

Authors:  Paulo L Lizano; Matcheri S Keshavan; Neeraj Tandon; Ian T Mathew; Suraj Sarvode Mothi; Debra M Montrose; Jeffrey K Yao
Journal:  Schizophr Res       Date:  2015-12-11       Impact factor: 4.939

2.  Decreased serum TNF-alpha levels in chronic schizophrenia patients on long-term antipsychotics: correlation with psychopathology and cognition.

Authors:  Meng Han Lv; Yun Long Tan; Shao Xiao Yan; Li Tian; Da Chun Chen; Shu Ping Tan; Zhi Ren Wang; Fu De Yang; Jin H Yoon; Giovana B Zunta-Soares; Jair C Soares; Xiang Yang Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-06-24       Impact factor: 4.530

3.  Markers of inflammation in schizophrenia: association vs. causation.

Authors:  Peter Manu; Christoph U Correll; Martien Wampers; Alex J Mitchell; Michel Probst; Davy Vancampfort; Marc De Hert
Journal:  World Psychiatry       Date:  2014-06       Impact factor: 49.548

4.  A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression.

Authors:  D R Goldsmith; M H Rapaport; B J Miller
Journal:  Mol Psychiatry       Date:  2016-02-23       Impact factor: 15.992

5.  Interleukin-17 Alteration in First-Episode Psychosis: A Meta-Analysis.

Authors:  Xinyu Fang; Yi Zhang; Weixing Fan; Wei Tang; Chen Zhang
Journal:  Mol Neuropsychiatry       Date:  2017-10-28

6.  Inflammation in Schizophrenia: Cytokine Levels and Their Relationships to Demographic and Clinical Variables.

Authors:  Ellen E Lee; Suzi Hong; Averria Sirkin Martin; Lisa T Eyler; Dilip V Jeste
Journal:  Am J Geriatr Psychiatry       Date:  2016-10-17       Impact factor: 4.105

Review 7.  Bridging Autism Spectrum Disorders and Schizophrenia through inflammation and biomarkers - pre-clinical and clinical investigations.

Authors:  Joana Prata; Susana G Santos; Maria Inês Almeida; Rui Coelho; Mário A Barbosa
Journal:  J Neuroinflammation       Date:  2017-09-04       Impact factor: 8.322

Review 8.  Functional Implications of the IL-23/IL-17 Immune Axis in Schizophrenia.

Authors:  Monojit Debnath; Michael Berk
Journal:  Mol Neurobiol       Date:  2016-11-29       Impact factor: 5.590

Review 9.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

10.  Immuno-inflammatory changes across phases of early psychosis: The impact of antipsychotic medication and stage of illness.

Authors:  Skylar Kelsven; Camilo de la Fuente-Sandoval; Cristian L Achim; Francisco Reyes-Madrigal; Heline Mirzakhanian; Isabel Domingues; Kristin Cadenhead
Journal:  Schizophr Res       Date:  2020-02-20       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.